Brain cholesterol therapy for Huntington's disease - Does it make sense?

References

[1] Tabrizi SJ, Schobel S, Gantman EC, et al. A biological classification of Huntington's disease: the Integrated Staging System. Lancet Neurol. 2022;21:632-644.

[2] Valenza M, Birolini G, Cattaneo E. The translational potential of cholesterol-based therapies for neurological disease. Nat Rev Neurol. 2023;19:583-598.

[3] Birolini G, Valenza M, Ottonelli I, et al. Chronic cholesterol administration to the brain supports complete and long-lasting cognitive and motor amelioration in Huntington's disease. Pharmacol Res. 2023;194:106823.

[4] Kacher R, Lamazière A, Heck N, et al. CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease. Brain. 2019;142:2432-2450. (ClinicalTrials.gov NCT05541627).

[5] Haider A, Zhao C, Wang L, et al. Assessment of cholesterol homeostasis in the living human brain. Sci Transl Med. 2022;14(665):eadc9967.

[6] Schultz JL, Nopoulos PC, Killoran A, et al. Statin use and delayed onset of Huntington's disease. Mov Disord. 2019;34(2):281-285.

[7] Ghaznavi H, Afzalipour R, Khoei S, et al. New insights into targeted therapy of glioblastoma using smart nanoparticles. Cancer Cell Int. 2024;24:160.

[8] ClinicalTrials.gov NCT03806478.

[9] McColgan P, Thobhani A, Boak L, et al. Tominersen in adults with manifest Huntington's disease. N Engl J Med. 2023;389:2203-2205.

[10] Jensen MP, Barker RA. Disease-modification in Huntington's disease: moving away from a single-target approach. J Huntington's Dis. 2019;8:9-22.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.